Chicharros USA - bolsa internacional

Jajajajajaj,,,tomaaaa!!!! y con volumen.

Hoy ni las había mirado casi

IMUC pues ala mañana te llevas la chochona jajaja

IMUC,,,,buuffff!!!! las llevo a 0,38 y 0,32,,,recuperar ya es un triunfo.

IMUC pues a recuperar y a llevarte un peñizco que mno alegro yo de estas cosas cuándo ganáis leches ándeleeee

IMUC

Estoy viendo 0.4 tras cierre

IMUC

Han llegado hasta alcanzar 0.47, yo las llevo a 0.42 y 0.38, a ver mañana.

IMUC, las llevo a 2,5 $ compradas en julio, jejejje

a ver si recupero ;)

https://www.streetinsider.com/dr/news.php?id=13598278

  ImmunoCellular Therapeutics (IMUC) Says it Achieved Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program

December 13, 2017 4:19 PM

ImmunoCellular Therapeutics, Ltd. ((NYSE: IMUC) announced today that it has achieved a key milestone in its research-stage Stem-to-T-Cell immuno-oncology program. The milestone represents an important step toward stimulating the patient's immune system to produce an unlimited supply of killer T cells that specifically target and destroy tumor cells with minimal side effects. This approach could be effective in treating many types of cancers. The research team at ImmunoCellular successfully packaged a T cell receptor (TCR) DNA sequence into a lentiviral vector, which was then used to transfect human hematopoietic stem cells. The Company has been able to verify successful transfer of genetic material into the stem cells, and plans to continue to work toward optimizing the transfection process. The Company believes that this completed phase of the Stem-to-T-Cell development is an important component of the proof-of-concept work for this technology, and represents a critical step in advancing toward preclinical testing.

"We are excited to have achieved this critical initial milestone in our Stem-to-T-Cell program, and to have generated a body of scientific evidence of successful transfection and proof that the transfected human hematopoietic stem cells bearing the TCR were able to grow robustly for several generations," said Steven J. Swanson, PhD, Senior Vice President, Research. "We and our collaborators are on schedule to undertake next anticipated steps designed to enhance the transfection process and advance toward preclinical testing. We remain committed to our vision to develop solutions for intractable cancers, extending the lives of cancer patients, and providing hope for a potential cure. We believe that our Stem-to-T-Cell program is potentially a game-changing treatment for cancer."

Anthony J. Gringeri, PhD, President and Chief Executive Officer commented: "We are proud of the achievements of our research team and the important scientific validation of our Stem-to-T-Cell program generated to date. We believe that our stem cell technology represents a major step forward in immuno-oncology, and has the potential for meaningful advantages over other novel immuno-oncology technologies, including use in combination approaches. With our strengthened financial condition and cash reserves, we intend to continue to focus our resources on achieving additional research milestones over the next 18 months. We are also continuing to explore potential collaborations for our clinical programs and other strategic alternatives for our Company."

Buenas noches

muy muy de acuerdo sniper, el juego es mental y de bolsillo, lo que cada uno pueda / podamos soportar, es como el póker además de suerte....hay que saber jugar!!!

voy a leer bien el foro que algo leí de IMUC joder menos mal porque vaya dos semanas llevo